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ABSTRACT
RNA interference (RNAi) has been revolutionary for
the specific inhibition of gene expression. However,
the application of RNAi has been hampered by the
fact that many siRNAs induce dose-dependent
unwanted secondary effects. Therefore, new
methods to increase inhibition of gene expression
with low doses of inhibitors are required. We have
tested the combination of RNAi and U1i (U1 small
nuclear RNA—snRNA—interference). U1i is based
on U1 inhibitors (U1in), U1 snRNA molecules
modified to target a pre-mRNA and inhibit its gene
expression by blocking nuclear polyadenylation.
The combination of RNAi and U1i resulted in
stronger inhibition of reporter or endogenous
genes than that obtained using either of the tech-
niques alone. The increased inhibition observed is
stable over time and allows higher inhibition than
the best obtained with either of the inhibitors alone
even with decreased doses of the inhibitors. We
believe that the combination of RNAi and U1i will
be of interest when higher inhibition is required or
when potent inhibitors are not available. Also, the
combination of these techniques would allow func-
tional inhibition with a decreased dose of inhibitors,
avoiding toxicity due to dose-dependent unwanted
effects.
INTRODUCTION
Inhibition of gene expression has been successfully applied
for functional studies and oﬀers great promise for thera-
peutic applications. In most laboratories, the expression of
the gene of interest is inhibited using RNA interference
(RNAi). The inhibitors that mediate RNAi are
double-stranded small RNA molecules called small
interfering RNAs (siRNAs). For RNAi, exogenous
siRNAs are coupled to the RNA-induced silencing
complex (RISC) which induces target mRNA cleavage
and as a result, target gene expression is inhibited (1).
RISC can also load endogenous small non-coding RNAs
called microRNAs (miRNAs). miRNAs are transcribed in
the nucleus as long primary transcripts or pri-miRNAs
which are cleaved into pre-miRNAs, imperfectly paired
stem–loop miRNA precursors (2). pre-miRNAs are then
exported to the cytoplasm where they bind Dicer, which
processes pre-miRNAs into mature double-stranded
miRNAs recognized by RISC (3,4). The RISC retains
single-stranded mature cellular miRNAs, which can
usually bind to their targets with non-perfect complemen-
tarity. Binding of the ‘seed’ sequence formed by nucleo-
tides 2–7 of the 50-end of the miRNA is suﬃcient for target
recognition (5). miRNA binding to the target induces a
RISC-mediated translation inhibition and/or mRNA de-
stabilization (6). The cellular silencing machinery can be
also used to express siRNAs from exogenous genes. Genes
can be designed to transcribe siRNA precursor molecules
similar to pre-miRNAs, called small hairpin RNAs
(shRNAs) (7). After transcription, shRNAs follow a
similar pathway to miRNAs and are loaded into RISC,
where they behave akin to synthetic siRNAs leading to
target mRNA cleavage.
RNAi is not as speciﬁc as originally thought. Under
certain circumstances, functional siRNAs can lead to
unwanted eﬀects. The three major reasons for this are:
(i) some siRNA molecules are sensed by the cell leading
to activation of the interferon response (8,9); (ii)
overexpression of siRNAs can saturate the cellular
silencing machinery which is required to control the ex-
pression of many genes involved in essential cellular
processes (10); and (iii) many siRNAs are not speciﬁc
for their target and can act as miRNAs to inhibit the ex-
pression of other genes which could be required for proper
cell functioning (11,12). As unwanted eﬀects are
dose-dependent (11,12), it is essential to develop protocols
that improve siRNA performance or allow the eﬃcient
dose of siRNA to be reduced to a minimum thus
avoiding unwanted eﬀects.
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nuclear RNA—U1 snRNA—interference (U1i) (13,14).
U1 snRNA coupled to U1-70K and other cellular
proteins forms a mature nuclear ribonucleoprotein
(U1 snRNP), which is a well-studied constitutive splicing
factor (15). U1 snRNP functions in splicing by binding the
pre-mRNA via a base pairing interaction between nucleo-
tides 2–11 of U1 snRNA and the 50-splice site sequence.
Aside from this splicing function, U1 snRNP can also act
as a potent inhibitor of gene expression by inhibiting
pre-mRNA 30-end formation (16). When nt 2–11 of U1
snRNA bind to the 30-end of a pre-mRNA, U1 snRNP
inhibits pre-mRNA polyadenylation. The molecular
mechanism that mediates this inhibition has been
well-characterized. After U1 snRNP binding to the
target pre-mRNA, the U1-70K component of the U1
snRNP directly inhibits polyadenylation and therefore,
gene expression (17,18) (Figure 1A). Inhibited
pre-mRNA is cleaved at the 30-end but it is not
polyadenylated. Without a polyA tail, the pre-mRNA
fails to mature and is rapidly degraded in the nucleus
leading to reduced expression.
This inhibitory activity of U1 snRNP forms the basis of
U1i silencing technology. U1i requires expression of an
exogenous 50-end mutated U1 snRNA designed to base
pair to the 30-terminal exon of a target gene. The U1
snRNA inhibitor (U1in) binds target mRNA and blocks
expression by hindering polyadenylation (13,14).
Expression of endogenous genes has been inhibited by
U1i after transient or stable transfections, thus indicating
the good speciﬁcity and low toxicity of this technique (14).
Expression of multiple U1ins that target diﬀerent parts of
the terminal exon of the same gene results in synergistic
enhanced inhibition (14). U1i has been shown to be
eﬀective against HIV replication and works in animal
models and thus holds great promise for knock-down
studies and gene therapy applications [(19), X. Abad and
P. Fortes, unpublished data]. The rules that govern U1i
were ﬁrst studied with reporter genes (14). U1ins are ex-
pressed from plasmids that include U1 snRNA promoter
and terminator sequences. A U1in against an accessible
target site located in the 30-terminal exon of a reporter
mRNA, inhibits reporter expression and does not alter
the expression of other genes. However, when target
sites are located outside the 30 terminal exon or when
they form secondary structures, inhibition is lost (14,17).
As RNA secondary structure is diﬃcult to predict, selec-
tion of good target sites is a challenge that generally
decides the success of the technique.
RNAi and U1i aﬀect target mRNA expression by dif-
ferent mechanisms and in diﬀerent cell compartments.
While U1i aﬀects the nuclear metabolism of the target
RNA, RNAi decreases the stability of the RNA in the
cytoplasm, where the RISC complex is located.
Therefore, both techniques could be combined without
increasing the risk of saturation of their silencing
machineries. In this study, we show that the combination
of RNAi and U1i results in increased inhibition of
reporter and endogenous genes. The beneﬁts of the com-
bination have been quantiﬁed using luciferase reporters.
The results show improved inhibition when shRNAs of
diﬀerent strengths are expressed in combination with
U1i inhibitors. This synergism between U1i and RNAi
allows the dose of both or either of the inhibitors to be
decreased and higher inhibition than when only one of the
inhibitors is used to still be obtained. We believe that the
combination of RNAi and U1i will allow successful inhib-
ition even when good inhibitors for a speciﬁc target have
Figure 1. Schematic of U1i. (A). When the 50-end of endogenous U1 snRNA base pairs to a target sequence located in the 30-terminal exon, U1
snRNP inhibits pre-mRNA polyadenylation (pA). Thus, maturation of the pre-mRNA is blocked, mRNA stability, transport to the cytoplasm, and
translation are decreased and therefore gene expression is inhibited. 30-terminal exon sequences are indicated. Intron is depicted with a dashed line.
(B and C). The 50-end of U1 snRNA has been modiﬁed to base pair Notch1 pre-mRNA resulting in U1inaNotch1. U1inaNotch1 should bind
sequence CACUGCCU located four times in the Notch1 30-UTR. Two repeats locate at positions 7924 and 8653, upstream of the ﬁrst
polyadenylation site. Two repeats locate at positions 10043 and 10138, upstream of an alternative polyadenylation site. An alignment of the four
Notch1 target sites and neighbouring sequences is also shown.
e136 Nucleic Acids Research, 2010,Vol.38, No. 13 PAGE 2 OF 11not been identiﬁed. Furthermore, this combination will
allow the dose of inhibitors to be decreased which may
lower the risk of unwanted eﬀects in functional studies and
therapeutic applications.
MATERIALS AND METHODS
Cell lines and plasmids
HeLa and 293 cells were obtained from the ATCC and
cultured in DMEM medium, supplemented with 10%
FBS and 1% penicillin–streptomycin, at 37 Ci na5 %
CO2 atmosphere. All cell culture reagents were obtained
from Gibco BRL/Life Technologies. Plasmid pRL-SV40
(Promega) was used as Renilla luciferase transfection
control. pGL3-Promoter (Promega) was used as Fireﬂy
luciferase (Photinus pyralis, GenBank Accession
No.M15077) expressing plasmid in Figure 3A–C.
pNFkb-Luc (NFkb 3xLuc; Clontech Co) was used to ex-
press Fireﬂy luciferase under NFkb promoter (Figure 2B).
pLuc-U1in (Figures 3B, 4 and 5) was cloned by ligation of
base-paired oligonucleotides (Sigma) with the U1inaLuc
sequence (Table 1) into the XbaI-NotI site of
pGL3-Promoter. A pGem plasmid (Promega) that
contains U1 snRNA gene, including promoter and
termination sequences in the BamHI site was used to
express wild-type U1 snRNA (pGemU1inWT) (14). This
plasmid was used as a control for U1i inhibition. Plasmid
expressing U1inaLuc has already been described
[pGemU1inMut; (17)]. pGemU1inaNotch1, expressing
U1inaNotch1, was cloned by ligation of base-paired oligo-
nucleotides with the U1inaNotch1 sequence (Table 1) into
the BclI-BglII site of pGemU1inWT. The exact sequence
of the 50-end of U1inaNotch1 is shown in Figure 1B.
Ligation of the U1 sequences from pGemU1inWT and
pGemU1inaNotch1 digested with EcoRI and HincII
into the same sites of pMSCV-Puro (Clontech) resulted
in pMSCV-U1inWT and pMSCV-U1inaNoctch, respect-
ively. The MISSION Luciferase shRNA pLKO.1-puro
vector was used to deliver all shRNAs targeting Fireﬂy
luciferase. shRNAs expressed from this plasmid are
transcribed from a U6 promoter. The 50-end of the
shRNA starts with the sense strand and is followed by a
CTCGAG loop, the antisense strand and UU. The sense
and antisense strands have perfect complementarity and
are 21-nt long. Plasmid expressing shaLuc159 is now com-
mercially available (SHC007 Sigma). Plasmid expressing
shaNotch1 was cloned by ligation of base-paired oligo-
nucleotides with the shaNotch1 sequence (Table 1) into
the HindIII-BglII site of pSuper (7). An irrelevant
Figure 2. Inhibition of endogenous Notch1 expression and function with RNAi and U1i. (A). Inhibition of endogenous Notch1 expression. HeLa
cells were transfected with a control plasmid (mock), with plasmids expressing U1inaNotch1 (U1in) or shaNotch1 (sh) at the highest dose, or half of
the highest dose (X/2) or with the combination of plasmids expressing U1inaNotch1 and siaNotch1 (sh/2+U1in/2). HeLa cell lysates were collected
3 days after transfection and Notch1 (upper box) and actin (lower box) expression was evaluated in two independent western blots. (B). Functional
assay for Notch1 gene silencing. 293 cells were co-transfected with pNFkb-Luc, Renilla luciferase control and the plasmids described in A. Luciferase
activity was evaluated 3 days after transfection and the data obtained were corrected for equal transfection eﬃciency. Results were plotted to indicate
the fold inhibition obtained in each case. Fold inhibition was calculated as the ratio of the luciferase activity obtained in mock transfected cells versus
the luciferase activity obtained in cells expressing the indicated inhibitor. Error bars denote standard deviations of three independent experiments.
(C and D) Analysis of the silencing of endogenous Notch1 over time. (C) Pools of clones of HeLa cells stably transfected with a control plasmid
(mock), or plasmids expressing U1inaNotch1(U1in), shaNotch1 (sh) or both (sh+U1in) were used to evaluate Notch1 (upper box) and actin (lower
box) expression by western blot. (D) Representative clones of HeLa cells expressing U1WT or U1inaNotch1 were transfected with a control plasmid
(mock and U1in, respectively) or with a plasmid expressing shaNotch1 (sh and sh+U1in, respectively). Stably transfected pools of clones were used
to determine Notch1 (upper box) or actin (lower box) expression by western blot.
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measured in HeLa cells co-transfected with a plasmid expressing Fireﬂy luciferase and a control plasmid or plasmids expressing the indicated
shRNA. The shRNAs are named according to the position of the ﬁrst nucleotide they bind to in luciferase mRNA. (B–D) Fold inhibition of
luciferase activity with decreasing doses of inhibitors. Luciferase activity was measured in HeLa cells co-transfected with a plasmid that expresses
Fireﬂy luciferase and a control plasmid or the indicated amount of plasmids expressing luciferase inhibitors (see ‘Materials and Methods’ section for
details). Plasmids used express U1inaLuc (B), shaLuc1546 (shH1, C) and shaLuc163 (shS, D). The fold inhibition is indicated for each inhibitor.
Error bars are standard deviations of nine diﬀerent experiments. Note that the scale is diﬀerent for each ﬁgure.
Table 1. List of inhibitors used in this study
Target gene Name Target sequence Position
Notch1 U1inaNotch1 CACUGCCU 7924, 8653, 10043 and 10138
shaNotch1 ACACCAACGUGGUCUUCAA 4878
Fireﬂy (P. pyralis) luciferase U1inaLuc CCUGCCAUGGAACUA Exogenous 30-UTR
shaLuc34 GCGCCAUUCUAUCCGCUGGAA 34
shaLuc153 CACUUACGCUGAGUACUUCGA 153
shaLuc154 (L1) ACUUACGCUGAGUACUUCGAA 154
shaLuc158 (H2) ACGCUGAGUACUUCGAAAUGU 158
shaLuc159 CGCUGAGUACUUCGAAAUGUC 159
shaLuc160 GCUGAGUACUUCGAAAUGUCC 160
shaLuc162 UGAGUACUUCGAAAUGUCCGU 162
shaLuc163 (S) GAGUACUUCGAAAUGUCCGUU 163
shaLuc164 AGUACUUCGAAAUGUCCGUUC 164
shaLuc168 CUUCGAAAUGUCCGUUCGGUU 168
shaLuc221 CAAAUCACAGAAUCGUCGUAU 221
shaLuc224 AUCACAGAAUCGUCGUAUGCA 224
shaLuc225 UCACAGAAUCGUCGUAUGCAG 225
shaLuc228 CAGAAUCGUCGUAUGCAGUGA 228
shaLuc229 AGAAUCGUCGUAUGCAGUGAA 229
shaLuc230 (L2) GAAUCGUCGUAUGCAGUGAAA 230
shaLuc601 UCUACUGGUCUGCCUAAAGGU 601
shaLuc743 GAAUGUUUACUACACUCGGAU 743
shaLuc745 AUGUUUACUACACUCGGAUAU 745
shaLuc754 ACACUCGGAUAUUUGAUAUGU 754
shaLuc755 CACUCGGAUAUUUGAUAUGUG 755
shaLuc976 GCGGUUGCCAAGAGGUUCCAU 976
shaLuc1193 UGUCCGGUUAUGUAAACAAUC 1193
shaLuc1510 AGUCAAGUAACAACCGCGAAA 1510
shaLuc1546 (H1) GUUGUGUUUGUGGACGAAGUA 1546
Position and sequence of the target is also indicated.
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negative control. shRNAs expressed from pSuper are
transcribed from a H1 promoter, start with the sense
strand followed by a TTCAAGAGA loop, the antisense
strand and end with UU. The sense and antisense strands
have perfect complementarity and are 19-nt long. Ligation
of the shaNotch1 gene sequences from pSuper digested
with NotI and XhoI and ﬁlled in with Klenow into the
XhoI site of pIRESNeo (Clontech) resulted in
pNeoshaNotch1. To produce pNeoU1in/shaNotch1,
pNeoshaNotch1 was digested with BamHI and ligated
to U1 sequences digested with BamHI from
pGemU1inaNotch1. Irrelevant shRNA sequences and
U1WT gene were also cloned into the same sites as
negative controls. All clones were veriﬁed by sequencing
in an ABI Prism 310 genetic analyzer (Applied
Biosystems). Plasmid DNA was puriﬁed with a
Maxiprep kit (Marlingen) before transfection.
Cell transfections
To evaluate Notch1 expression, HeLa cells were trans-
fected with Lipofectamine 2000 (Invitrogen) and 4mgo f
the indicated plasmid per 5 10
5 cells, following the rec-
ommendations of the supplier. Seventy-four hours after
transfection, cells were harvested and western blot
analysis was performed. To test the eﬀect of inhibitors
on luciferase expression, HeLa or 293 cells were trans-
fected with calcium phosphate as described (20) and
were harvested 48-h post-transfection. A total of 150000
cells were transfected with 0.75mg of the plasmid express-
ing Fireﬂy luciferase, 0.25mg of pRL-SV40 (Promega) and
a total of 1mg of plasmids expressing the inhibitors, the
control inhibitor or a combination of both (0.5mgo f
plasmid expressing one inhibitor +0.5mg of plasmid ex-
pressing the control). Note that for the combination of
RNAi and U1i, 0.5mg of a plasmid expressing the
shRNA inhibitor was mixed with 0.5mg of a plasmid ex-
pressing the U1in. When indicated, a dilution of one or
both plasmids expressing the inhibitors was used. In all
cases, the total amount of plasmid transfected was
constant and transfection eﬃciency was controlled by
Renilla luciferase analysis. The amount of plasmid trans-
fected was chosen because (i) this amount results in a
transfection eﬃciency close to 100% with non-detectable
toxicity; (ii) transfection of increasing amounts (from 0.1
to 2mg) of a luciferase reporter plasmid results in a linear
response of luciferase expression; and (iii) transfection
of increasing amounts (from 0.05 to 1mg) of plasmids
expressing the inhibitors results in increased inhibition,
indicating that the system is not oversaturated
(Figure 3B–D). To obtain stably transfected cell lines,
HeLa cells were transfected with 2mg of linear
pMSCV-U1inaNoctch, pNeoU1in/shaNotch1 or the cor-
responding control plasmids and cells were selected for
longer than 1 month with 8mg/ml of puromycin or
1400mg/ml of G418, respectively. Cells stably expressing
pMSCV-U1inaNoctch or pMSCV-U1inWT were also
transfected with 2mg of linear pNeoshaNotch1 or the cor-
responding control plasmids and cells were selected with
G418 as indicated before.
Western blot
Whole cell lysates used for western blotting were prepared
by lysis of cells in RIPA buﬀer, centrifugation for 60min
at 15000r.p.m., and collection of the supernatant.
Proteins were separated by SDS–PAGE and transferred
to an Immobilon-P nylon membrane (Millipore) (21).
Notch1 protein was bound by antihNotch-1 antibody
(sc-6014-R; Santa Cruz) diluted 1/500 and actin by
antib-Actin antibody (A2066; Sigma) diluted 1/1000.
Horseradish peroxidase-conjugated secondary antibodies
(1:5000) were from Cell Signalling (#7074). Western blots
were revealed by chemiluminescence (NEL 101001; Perkin
Elmer) and quantiﬁed with Image Quant TL Software
(GE Lifesciences).
Luciferase activity measurements
Renilla and Fireﬂy luciferase activities were measured
using the Dual Luciferase System (Promega) as previously
described (22) in a Berthold Luminometer (Lumat LB
9507). The values obtained for Fireﬂy luciferase were
corrected for equal transfection eﬃciency with Renilla
luciferase activity. The fold inhibition of each inhibitor
was calculated as the ratio of the luciferase activity
obtained in mock transfected cells versus the luciferase
activity obtained in cells expressing the inhibitor studied.
Mock transfected cells express a matched reference
plasmid used as negative control expressing either
U1inWT or the shRNA of irrelevant sequence. By deﬁn-
ition, the reference plasmid has an inhibitory activity set
to 1.0.
Statistical analysis
Data are expressed as means±SD. Statistical analysis
was performed with Student’s t-test using the SPSS
software package (SPSS INC, Chicago, IL, USA).
Statistically signiﬁcant diﬀerences (P< 0.05) are indicated
with a star.
RESULTS AND DISCUSSION
Combination of RNAi and U1i results in stronger
inhibition of the expression of endogenous genes
To test the combination of RNAi and U1i in the inhib-
ition of the expression of a target gene, we ﬁrst designed
siRNAs and U1in inhibitors against an endogenous gene.
We decided to target human Notch1, a gene of therapeutic
interest (23). Notch1 is a transmembrane receptor
involved in transduction of developmental signals in
most eukaryotes. Notch1 ligand binding induces the pro-
teolytic cleavage of the intracellular domain of Notch1,
which translocates to the nucleus and activates gene ex-
pression. Overexpression of the intracellular domain of
Notch1 can induce breast cancer and T-cell transform-
ation that results in T-cell acute lymphoblastic leukemias
and lymphomas (23,24). Therefore, inhibition of Notch1
could have therapeutic applications for the treatment of
several tumours. Aberrant Notch signalling can also
trigger signals implicated in promoting autoimmune
diseases. However, the cellular response to Notch
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activation context. Thus, Notch signalling can also induce
responses that are critical to negatively regulating immune
responses or suppressing carcinogenesis, for instance in
neuroendocrine tumours (25,26).
We designed a U1in targeting the sequence CACUGCC
U in Notch1 pre-mRNA (Figure 1B, U1inaNotch1,
Table 1). We chose this sequence because it is repeated
four times in Notch1 30-terminal exon. Two repeats
locate before the ﬁrst polyadenylation site and the other
two before an alternative polyadenylation signal.
Homology among the four target sites is not extended
further (Figure 1C). We designed four siRNAs targeting
Notch1. Three siRNAs were designed following recom-
mendations published by Reynolds et al. (27). These
authors list requirements that functional siRNAs must
fulﬁl and describe an algorithm that helps to design
potent siRNA inhibitors. According to their results, func-
tional siRNAs have a score >6 out of a maximum of 10.
Thus, we designed three siRNAs targeting Notch1 that
have a score of 8 or 9. These siRNAs should also be
potent inhibitors according to Matveeva et al.
[Supplementary Table S1 (28)]. We also used an additional
siRNA sequence with a score of 3 as calculated following
Reynolds et al. (27), as this has been reported to be an
eﬃcient inhibitor of Notch1 expression (29). A pSuper
backbone was used to construct plasmids that express
the four designed siRNAs (7). When these plasmids were
transfected into HeLa cells down-regulation of Notch1
protein was observed with the vector expressing the low
score siRNA already published. However, only one of the
plasmids expressing a high score siRNA was able to
down-regulate Notch1 eﬃciently as detected by western
blot analysis (Table 1, Figure 2A). Transfection of the
plasmid expressing U1inaNotch1 into HeLa cells also
resulted in down-regulation of Notch1 protein. A 50%
reduction of the amount of transfected plasmid expressing
either of the inhibitors resulted in a less eﬃcient
down-regulation of Notch1 expression. This indicated
that inhibition was not saturated in cells transfected with
half a dose of the plasmids that express the inhibitors.
Quantitation of the western blot indicated that both in-
hibitors down-regulate Notch1 expression to similar levels
under the conditions used (Supplementary Figure S1).
Surprisingly, co-transfection of half of the dose of the
plasmids expressing the U1inaNotch1 and the
shaNotch1 resulted in a strong down-regulation of
Notch1. Quantitation of the western blot indicated that
the co-expression of U1inaNotch1 and shaNotch1
resulted in stronger inhibition of Notch1 than the expres-
sion of the highest dose of either of the inhibitors on
their own.
We also wanted to evaluate the functional relevance of
Notch1 down-regulation. Notch1 expression increases
NFkb activity by facilitating its nuclear retention (30),
resulting in increased expression from NFkb speciﬁc pro-
moters. Thus, 293 cells were transfected with a plasmid
that expresses Fireﬂy luciferase under an NFkb speciﬁc
promoter (pNFkb-Luc) and a plasmid that expresses
Renilla luciferase independently of Notch1 expression, as
an internal control. We also co-transfected a control
plasmid, plasmids expressing U1inaNotch1 or
shaNotch1 at the highest dose or half dose and the com-
bination of plasmids expressing U1inaNotch1 and
shaNotch1. Luciferase activity was evaluated 2 days
after transfection and the data obtained were corrected
with Renilla luciferase values. Luciferase measurements
allowed evaluation of Notch1 function with a wider
range of quantiﬁcation than western blots. The results
showed that all inhibitors decreased Fireﬂy luciferase ex-
pression (Figure 2B). The fold inhibition was similar in
cells transfected with similar doses of plasmids expressing
U1inaNotch1 or shaNotch1. As observed before,
co-transfection of half of the dose of the plasmids express-
ing the U1inaNotch1 and the shaNotch1 resulted in the
highest fold inhibition.
To address the stability of Notch1 silencing over time
we used cells displaying long-term expression of the inhibi-
tors. Two sets of experiments were performed. Notch1
expression was ﬁrst evaluated in pools of HeLa clones
which stably express a control plasmid or plasmids ex-
pressing U1inaNotch1, shaNotch1 or both. Stability of
expression was achieved as the pools of clones were
selected and ampliﬁed for longer than 1 month. The
results showed that the strongest decrease in Notch1 ex-
pression was observed in cells expressing both
U1inaNotch1 and shaNotch1 (Figure 2C). Furthermore,
we performed a similar experiment with transfections in
tandem. We ﬁrst isolated clones of HeLa cells stably trans-
fected with a plasmid expressing U1inaNotch1 or U1WT,
as a control. Then a control clone and a representative
clone expressing U1inaNotch1 were transfected with a
control plasmid or a plasmid expressing shaNotch1.
Pools of clones that express these plasmids stably were
selected and ampliﬁed for longer than 1 month. Notch1
expression was evaluated by western blot in extracts
isolated from these clones. The results showed that the
strongest inhibition of Notch1 was observed in cells
stably expressing both U1inaNotch1 and shaNotch1
(Figure 2D).
Identiﬁcation of U1in and siRNA inhibitors targeting
luciferase expression
We wanted to evaluate the inhibition obtained by the
combination of U1i and RNAi in a more quantitative
and direct manner. Measurement of luciferase activity
is very sensitive and allows quantiﬁcation within a
broad linear range. Therefore, we decided to design
novel inhibitors that target Fireﬂy luciferase based on
U1i and RNAi. The siRNAs targeting Fireﬂy luciferase
were selected using the algorithm described by the RNAi
Consortium (TRC). All possible siRNAs of 21-mer
derived from Fireﬂy luciferase mRNA sequence were
rewarded for having the weakest base pairing at
the 30-end and the strongest at the 50-end, for a GC
content between 30 and 50% and for the presence of AT
base pairs at positions 6–11. Candidates were penalized
when they contained a repeat of four bases in a row, an
AA start and internal loops. The penalties and rewards are
speciﬁed at http://www.broad.mit.edu/science/projects/
rnai-consortium/trc-shrna-design-process. We then chose
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Most of these siRNAs should also be potent inhibitors
according to Matveeva et al. [Supplementary Table S1
(28)]. A pLKO.1 backbone was used to construct
plasmids that express the 25 siRNAs from a precursor
shRNA. These shRNAs were named according to the
position of the ﬁrst nucleotide they bind to in Fireﬂy
luciferase mRNA. Three hot spots targeted by the best
predicted shRNAs were detected: 9 shRNAs target se-
quences from nucleotides 153–189, 6 shRNAs nucleotides
221–251 and 4 positions 743–776. The remaining 6
shRNAs base pair to sequences that were far from
targets of other selected shRNAs.
To evaluate Fireﬂy luciferase down-regulation by the
selected shRNAs, HeLa cells were co-transfected with
pGL3-Promoter, which expresses Fireﬂy luciferase, and
control plasmids or plasmids expressing each of the
shRNAs to be assayed. A plasmid that expresses Renilla
luciferase was also co-transfected as an internal control.
Cells were collected at 48-h post-transfection and
luciferase activity was evaluated in cell extracts. Renilla
luciferase activity was similar in all cases, suggesting com-
parable transfection eﬃciency in all cases and speciﬁcity of
the shRNAs for Fireﬂy luciferase. The fold inhibition of
each shRNA was calculated as the ratio of the luciferase
activity obtained in mock transfected cells versus the
luciferase activity obtained in cells expressing the inhibitor
studied (Figure 3A). Three shRNAs were very eﬃcient as
they showed inhibition of 10–20 fold, which corresponds
to a decrease in expression of over 90% (Supplementary
Table S1). Three shRNAs were standard as they showed a
3-5 fold inhibition, which represents a 70–80% decrease in
expression. Most of the shRNAs tested (19/25) were the
least eﬀective as inhibition was <3-fold, a
down-regulation <70%. We were surprised by the low
success of our shRNAs. These shRNAs should express a
functional siRNA core, given that the siRNA sequence
has been designed using algorithms built from the
analysis of a large number of eﬀective and ineﬀective
siRNAs and a better understanding of the molecular
mechanisms that drive RNAi (27,31). Also, our shRNA
design parameters, such as stem length, core placement
and loop selection have been successfully used by many
others (see ‘Materials and Methods’ section for details).
We cannot rule out that some genes such as luciferase
could be less sensitive to inhibition than others.
Five shRNAs were selected for further studies: two ef-
ﬁcient shRNAs, shaLuc1546 and shaLuc158, that target
luciferase with high potency and which, for simplicity,
were renamed shH1 and shH2, respectively; one
standard shRNA, shaLuc163, renamed shS, and two
shRNAs with low potency, shaLuc154 and shaLuc230,
renamed shL1 and shL2.
Instead of designing a novel U1in targeting Fireﬂy
luciferase, we introduced into this gene a target sequence
for U1inMut. U1inMut has been previously used to target
an exogenous sequence in the 30-UTR of Renilla luciferase
mRNA resulting in a 10–20 fold decrease in Renilla
luciferase activity (14). Similarly, U1inMut decreased the
expression from Fireﬂy luciferase gene containing the
U1inMut target (pLuc-U1in), but the inhibition was
only 4-fold (Figure 3B). The diﬀerence in the inhibition
obtained with Renilla and Fireﬂy luciferases could reﬂect
the eﬀect of target neighbour sequences. We consider that
a 4-fold inhibition of luciferase was ideal in our experi-
ments as it would allow a good quantiﬁcation of increased
inhibitions when U1i and RNAi based luciferase inhibi-
tors are combined. In this study, we decided to rename
U1inMut as U1inaLuc, for clarity (Table 1).
Fold inhibition of Fireﬂy luciferase expression
decreased when the amount of transfected plasmid ex-
pressing the shRNAs or U1in targeting Fireﬂy luciferase
was decreased (Figures 3B–D). This result was obtained
when both eﬃcient (shH1, Figure 3C) or standard (shS,
ﬁg 3D) shRNAs were used. This is in line with previous
studies that have reported that lower doses of inhibitors
have reduced secondary eﬀects but result in weaker inhib-
ition (11,12).
Combination of shRNAs and U1in targeting luciferase
results in stronger inhibition of luciferase expression
HeLa cells were co-transfected as before with pLuc-U1in
and control plasmids or plasmids expressing the diﬀerent
luciferase inhibitors alone or in combination. Fold inhib-
ition of Fireﬂy luciferase expression in the presence of
shRNAs targeting Fireﬂy luciferase was identical when
pLuc-U1in or pGL3-Promoter plasmids were used, as
both plasmids only diﬀer in the few nucleotides that com-
prise the U1in target sequence (compare Figures 3 and 4).
As indicated above, when we transfected 1/2mg of the
plasmids expressing the inhibitors, the inhibition of
Fireﬂy luciferase expression was lower than when 1mg
of these plasmids was used for the transfection
(Figure 4). However, when 1/2mg of the plasmids ex-
pressing the shRNAaLuc was co-transfected with 1/2mg
of the plasmid expressing the U1inaLuc, Fireﬂy luciferase
expression was most strongly inhibited. The inhibition of
luciferase expression when shRNAs and U1in targeting
luciferase were combined was higher than when either of
the inhibitors was used alone at the highest possible dose
in our experimental settings (1mg). This statistically sig-
niﬁcant increased inhibition obtained by combining RNAi
and U1i was observed with shRNAs that target luciferase
with high potency (shH2, Figure 4A and shH1,
Figure 4B), with modest potency (shS, Figure 4C) and
with low potency (shL1, Figure 4D), but not upon com-
bination of U1in with shL2, which on its own only inhibits
<2-fold (Figure 4E). These results suggest that the com-
bination of both techniques could be necessary to achieve
functional inhibition of some genes, such as those that are
specially diﬃcult to target. Furthermore, the silencing
eﬃciency correlates with the eﬃciency of the shRNA
used. Standard or less-eﬃcient shRNAs combined with
U1in can only increase inhibition from 3–4 fold to 5–8
fold (Figures 4C and D). However, combination with
U1i can increase silencing eﬃciency of potent shRNAs
from 10–20 fold to 15–30 fold (Figure 4A and B). A
synergy index was calculated to evaluate whether the
increased inhibition obtained by combination of RNAi
and U1i represents a synergic eﬀect (Supplementary
Table S2). The synergy index shows that co-expression
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results in a synergistic inhibition of luciferase expression.
Increased inhibition was not observed when diﬀerent
shRNAs were combined. Combination of a potent and a
standard shRNA (Supplementary Figure S2A), and
standard and a less-eﬃcient shRNA (Supplementary
Figure S2B) or two less-eﬃcient shRNAs
(Supplementary Figure S2C) resulted in fold inhibition
similar to that obtained with the more potent inhibitor
used in the combination. Calculation of the synergy
index shows no synergism in these cases (Supplementary
Table S2). This suggests that the parallel application of
two small RNAs acting at diﬀerent positions of a target
mRNA is not suﬃcient to result in synergistic inhibition.
Therefore, the synergism that we observe on combining
RNAi and U1i is the result of the combination of these
two diﬀerent knock-down mechanisms.
Synergism between RNAi and U1i allows the eﬀective
dose of inhibitor to be decreased
Decreasing the dose of inhibitor leads to a decrease in
secondary eﬀects but also to a decrease in the inhibition
(Figure 3B–D) (11,12). Therefore, it would be interesting
to analyse whether strong inhibitions can still be obtained
when decreased doses of U1in and shRNA are used in
combination. To address this question, we ﬁrst used
decreasing doses of one of the inhibitors while maintaining
the amount of the second inhibitor constant. Doses tested
were 1/2, 1/4, 1/8 and 1/20mg of plasmid in the transfec-
tion. Initially, we analysed the combination of the potent
shH1 with U1inaLuc. When we decreased shH1
maintaining U1inaLuc constant, the synergistic inhibition
decreased gradually (Figure 5A, Supplementary Table S2).
The combination of 1/2mg of the plasmid expressing
U1inaLuc with 1/8 or 1/20mg of the plasmid expressing
shH1, resulted in inhibitions of luciferase that were not
signiﬁcantly diﬀerent to those obtained when 1mg of the
plasmid expressing shH1 was transfected alone, but were
higher than those obtained when only 1/2mg of the
plasmid expressing shH1 was transfected. When we main-
tained shH1 constant, a decrease in the plasmid expressing
U1inaLuc from 1/2 to 1/4mg caused the highest decrease
in the synergistic inhibition. The combination of 1/2mgo f
the plasmid expressing shH1 with 1/20mg of the plasmid
expressing U1inaLuc resulted in a inhibition of luciferase
that was not signiﬁcantly diﬀerent to that obtained when
1/2mg of the plasmid expressing shH1 was transfected
alone. Therefore, in this case, a decrease in the amount
of U1in led to a large reduction in the synergistic eﬀect.
When we combined dilutions of the plasmids expressing
the standard shS or U1inaLuc, we also observed that
lower doses of either of the inhibitors could be used that
still result in potent inhibitions (Figure 5B). However, in
this case lowering the dose of shS had less impact on the
strength of the synergistic inhibition than when shH1 was
used (Supplementary Table S2). The combination of
1/2mg of the plasmid expressing U1inaLuc with 1/8 or
1/20mg of the plasmid expressing shS, resulted in inhib-
itions of luciferase that were signiﬁcantly higher than
those obtained when 1mg of the plasmid expressing shS
was transfected alone. This suggests to us that, as
indicated above, the silencing eﬃciency of the synergy
Figure 4. Increased inhibition is observed when U1in is combined with potent, standard and poor shRNA inhibitors. Luciferase activity was
measured in HeLa cells transfected with a plasmid that expresses Fireﬂy luciferase and a control plasmid or plasmids expressing luciferase inhibitors.
1mg or 1/2mg (X/2) of plasmid expressing the inhibitor was used for transfection. Inhibitors were U1inaLuc, shH2 (shaLuc158, A), shH1
(shaLuc1546, B), shS (shaLuc163, C), shL1 (shaLuc154, D) and shL2 (shaLuc230, E) alone or a combination of U1inaLuc and shaLuc (shX/2
+U1in/2). The fold inhibition is indicated for each case. Error bars are standard deviations of nine diﬀerent experiments. Note that the scale is
diﬀerent for each ﬁgure.
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Decreasing the dose of plasmid expressing U1inaLuc
while maintaining shS constant, resulted in a gradual
decrease in the inhibition. The combination of 1/2mgo f
plasmid expressing shS with 1/4mg of plasmid expressing
of U1inaLuc, resulted in higher inhibition than that
obtained when 1mg of the plasmid expressing shS or
U1inaLuc was transfected alone. Further decreases in
plasmid expressing U1inaLuc resulted in inhibitions of
luciferase that were not signiﬁcantly diﬀerent to those
obtained when 1/2mg of the plasmid expressing shS was
transfected alone.
Finally, we tested the eﬀect on inhibition of decreasing
the amount of both inhibitors at the same time. When
the transfected amount of plasmids that express shS
and U1inaLuc was decreased simultaneously, luciferase
inhibition decreased very rapidly (Figure 5C).
Nevertheless, the combination of 1/8mg of plasmid ex-
pressing shS with 1/8mg of plasmid expressing U1inaLuc
resulted in similar inhibition than that obtained when 1mg
of the plasmid expressing shS or U1inaLuc was trans-
fected alone.
These results show that in general, combination of
RNAi and U1i allows the dose of the inhibitors to be
decreased and potent inhibition to still be achieved.
However, diﬀerent combinations of shRNAs and U1ins
are aﬀected by dilution of the inhibitors in a diﬀerent
manner. Therefore, for each combination of shRNA and
U1in we recommend that a careful analysis be made of the
inhibition obtained with several doses of inhibitors.
Concluding remarks
Our results show a synergistic eﬀect of the combination of
RNAi and U1i, indicating that these mechanisms can
work together to produce higher levels of inhibition than
those obtained by any of the techniques independently.
Further experiments will be required to clarify the exact
molecular mechanism underlying this phenomenon.
Increased inhibition could result if combination of both
methods can bypass a partial saturation obtained only
when any of the techniques is used independently. The
synergism could be the result of a nuclear decrease in
target RNA by U1i coupled to a cytoplasmic decrease of
the same target by RNAi. Thus, U1i action could decrease
the amount of targetable mRNAs in the cytoplasm. There,
it may be easier for RNAi to cleave a lower amount of
target. However, RNAi is capable of eﬃciently inhibiting
high concentrations of target mRNAs. RNAi has been
described to involve a catalytic reaction where RISC,
after target cleavage, is released to act on another target
molecule. Thus, a single activated RISC can undergo
multiple rounds of target mRNA cleavage (32).
Our work shows that when only low eﬃcient shRNAs
or U1in are available that target a speciﬁc gene, combin-
ation of both inhibitors could result in increased inhibition
that could allow proper gene function studies. Also, even
Figure 5. Increased inhibition observed by combination of U1i and RNAi allows the eﬀective dose of inhibitors to be decreased. Luciferase activity
was measured in HeLa cells transfected with a plasmid that expresses Fireﬂy luciferase and a control plasmid or the amount of plasmids expressing
luciferase inhibitors indicated at the bottom of the graph. Inhibitors were U1inaLuc, and shH1 (A) and shS (B and C) alone or a combination of
U1inaLuc and shaLuc. The fold inhibition is indicated for each case. A horizontal dotted line serves to mark the best fold inhibition obtained with
the best inhibitor (either a shRNA or a U1in) on its own. Error bars show standard deviations of nine diﬀerent experiments. Note that the scale is
diﬀerent for each ﬁgure.
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could increase inhibition. This may be of interest when a
high inhibition is mandatory, for instance when targeting
a replicative viral RNA. Also, this may allow the dose of
either of the inhibitors or both inhibitors to be decreased
thus, avoiding damaging secondary eﬀects and at the same
time adequate levels of inhibition to be obtained.
Furthermore, the combination of RNAi with U1i, allows
diﬀerent sequences in a gene of interest, diﬀerent genes in
a given pathway or diﬀerent viral or cellular genes
required for eﬃcient viral production to be targeted. In
this last case, the combination of RNAi and U1i could
serve to decrease the possibility of viral escape by selection
of viruses resistant to a single inhibitor. In conclusion, we
believe that the increased inhibition obtained by combin-
ation of RNAi and U1i will be of therapeutic interest as
this results in an improved protocol for the speciﬁc inhib-
ition of gene expression.
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